Design Therapeutics appoints Julie Burgess as Chief Accounting Officer

Design Therapeutics, Inc.

Julie Burgess appointed Chief Accounting Officer, effective September 13, 2021.
Annual base salary of $350,000, bonus up to 35%, and stock option for 135,000 shares.
Burgess previously SVP Finance at Otonomy; brings over 25 years of experience.
Dawn Giangiulio will cease as interim principal accounting officer but remain Controller.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Dawn Giangiulio

Interim Principal Accounting Officer

DSGN · Design Therapeutics, Inc.

Effective: 2021-09-13
Successor: Julie Burgess
Filed: August 20, 2021, 7:59 PM ET

Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.

Appointed

Julie Burgess

Chief Accounting Officer

DSGN · Design Therapeutics, Inc.

Effective: 2021-09-13
Filed: August 20, 2021, 7:59 PM ET

On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dawn Giangiulio changed role as Interim Principal Accounting Officer at Design Therapeutics, Inc..

Action: discontinue serving as
Role: Interim Principal Accounting Officer

Exact text from the filing

Upon the Effective Date, which is expected to be September 13, 2021, Dawn Giangiulio, the Company’s Controller and interim principal accounting officer, will discontinue serving as the Company’s interim principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Julie Burgess was appointed as Chief Accounting Officer at Design Therapeutics, Inc..

Action: appointed
Role: Chief Accounting Officer

Exact text from the filing

On August 18, 2021, the Board of Directors (the “Board”) of Design Therapeutics, Inc. (the “Company”) appointed Julie Burgess as the Company’s Chief Accounting Officer and principal accounting officer, effective upon the date she commences employment with the Company (the “Effective Date”).

View on SEC.gov

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-252071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.